ID
30369
Beschrijving
https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609
Link
https://clinicaltrials.gov/ct2/show/NCT00486954
Trefwoorden
Versies (1)
- 30-05-18 30-05-18 - Halim Ugurlu
Houder van rechten
GlaxoSmithKline (GSK)
Geüploaded op
30 mei 2018
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer
Blood Products and Blood Supportive Care Products, Paclitaxel Premedications
Similar models
Blood Products and Blood Supportive Care Products, Paclitaxel Premedications
C0371802 (UMLS CUI [1,2])
C1521826 (UMLS CUI [1,2])
C1519795 (UMLS CUI [1,2])
C0033045 (UMLS CUI-2)
C1519795 (UMLS CUI [1,2])